Cardiac amyloidosis on nuclear imaging of the heart using 11C-PiB PET/CT. Image courtesy of RSNA
Cardiac amyloidosis research is a growing area in cardiology thanks to the recent advent of new drug therapies to treat the disease. Several new studies on that topic were presented at Heart Failure 2026 in Barcelona, Spain, a four-day event organized by the Heart Failure Association of the European Society of Cardiology (ESC-HF).
Acoramidis data continued positive trends
Positive data on the FDA-cleared drug acoramidis (Attruby) from the Phase 3 ATTRibute-CM study were presented in a late-breaking session at Heart Failure 2026.[1] Overall, acoramidis increased serum transthyretin (sTTR) early and significantly reduced intra-individual sTTR variability compared to a placebo. Those changes are associated with a reduced risk of all-cause mortality. BridgeBio Pharma said the data further differentiates the drug from others in the treatment of transthyretin amyloid cardiomyopathy (ATTR-CM). The drug offers more than 90% TTR stabilization.